HAYA Therapeutics is a biotechnology company developing precision RNA-guided medicines that target the dark genome.
HAYA Therapeutics's investors include Eli Lilly, Schroders Capital, Earlybird Venture Capital, Sofinnova Partners, +ND Capital.
HAYA Therapeutics is headquartered in Lausanne, Switzerland.
HAYA Therapeutics is a biotechnology company developing precision RNA-guided medicines that target the dark genome.
HAYA Therapeutics is at the Grant stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"HAYA Therapeutics — Funding & Investors." VCBacked, September 1, 2025, https://www.vcbacked.co/company/haya-therapeutics. Accessed September 13, 2026.
VCBacked. (2025). HAYA Therapeutics — Funding & Investors. Retrieved September 13, 2026, from https://www.vcbacked.co/company/haya-therapeutics
{{cite web |title=HAYA Therapeutics — Funding & Investors |url=https://www.vcbacked.co/company/haya-therapeutics |website=VCBacked |access-date=September 13, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated